Emily R. Schulman


Schulman, Emily R.

Emily Schulman has extensive trial and appellate experience in white-collar matters, with particular emphasis on healthcare and financial industries. She has briefed and argued dozens of cases before the United States Courts of Appeals, and has tried more than 20 jury trials in the United States District Courts. Her practice focuses on internal and governmental investigations and white collar defense. She has extensive experience representing companies, boards of directors and their committees, and individuals in internal investigations, criminal litigation, government enforcement actions, and federal and state grand jury investigations involving allegations of healthcare fraud, false claims, economic fraud and securities violations.

Prior to joining private practice, Ms. Schulman served as an Assistant United States Attorney in the US Attorney's Office in Massachusetts for more than a decade. In that capacity, she investigated and prosecuted economic and white-collar fraud, money laundering and tax violations, and political and public corruption cases.

Honors & Awards

  • Selected by her peers for inclusion in the 2014-2018 editions of the Best Lawyers in America for her work in Criminal Defense: White-Collar.
  • Recognized as a leading attorney in the 2013, 2014 and 2015 editions of The International Who's Who of Business Crime Defence Lawyers, with a source recently saying she is a "very talented trial lawyer." Selected by clients and peers as being among the world's leading investigations lawyers in the 2015 edition of Who's Who Legal: Investigations.
  • Named a Life Sciences Star for outstanding government enforcement/investigations work in the 2012-2017 editions of LMG Life Sciences.
  • Selected as a Fellow of the Litigation Counsel of America, a peer-nominated, invitation only Trial Lawyer Honorary Society.

Publications & News


January 9, 2018

False Claims Act: 2017 Year-in-Review

False Claims Act recoveries topped $3.7 billion in fiscal year 2017, marking the eighth straight year of annual recoveries in excess of $3 billion.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

August 16, 2017

WilmerHale Lawyers Named Among the 2018 Best Lawyers in America®, Nine Recognized as Lawyers of the Year

Best Lawyers in America®—the oldest and most respected peer-review publication in the legal industry—recognizes 107 WilmerHale lawyers and names nine partners as Lawyers of the Year in its 24th edition.

January 31, 2017

False Claims Act: 2016 Year-in-Review

In 2016, the Department of Justice continued to give high priority to False Claims Act investigations and prosecutions. This WilmerHale Client Alert was republished by Pratt's Government Contracting Law Report.

November 9, 2016

LMG Life Sciences Ranks WilmerHale and Attorneys Among the Best

The 2016 guide highlights nine firm practices and 18 attorneys, recognizing work under three categories—Intellectual Property, Finance and Transactional, and Non-IP Litigation and Enforcement.

August 15, 2016

WilmerHale Lawyers Named Among the 2017 Best Lawyers in America®, Six Recognized as Lawyers of the Year

Best Lawyers in America®—a respected peer-review publication in the legal industry—recognizes 101 WilmerHale lawyers and names six partners as Lawyers of the Year in its 23rd edition.

January 12, 2016

False Claims Act: 2015 Year-in-Review

In 2015, the Justice Department continued to give high priority to False Claims Act investigations, bringing in nearly $3.6 billion in settlements and judgments.

December 7, 2015

Supreme Court To Address Permissibility and Scope of Implied Certification Liability Under the False Claims Act

On Friday, December 4, the Supreme Court agreed to hear a case raising the questions of whether implied certification liability is permissible under the False Claims Act and, if so, under what circumstances.

September 14, 2015

LMG Life Sciences Release 2015 Rankings, Again Names WilmerHale a "Life Cycle Firm"

In its latest edition, LMG Life Sciences recognizes eight WilmerHale practice areas and 16 attorneys, and for the fourth consecutive year names WilmerHale a "Life Cycle Firm."

October 17, 2014

Manufacturing Trouble: Is cGMP the Next Enforcement Frontier?

An article by Emily Schulman and Joshua Sharp, published in the October 17, 2014 edition of Bloomberg BNA's Pharmaceutical Law & Industry Report, Vol. 12, No. 41.

Recent Highlights

  • Persuaded US Attorney’s Office to decline to bring criminal or civil charges against a multinational pharmaceutical company in a multi-year health care fraud investigation;
  • Represented multinational pharmaceutical company in multiple, multi-year parallel civil and criminal investigations focusing on off-label marketing, anti-kickback and false claims allegations (global settlement ~ $425 million);
  • Represented Fortune 500 healthcare company in multi-year parallel federal criminal and civil FDCA and False Claims Act investigations;
  • Represented Director of Marketing for multinational pharmaceutical company in federal Anti-kickback and False Claims Act investigation;
  • Represented treatment facility physician in state Medicaid fraud investigation;
  • Represented pharmaceutical company in congressional inquiry into payments to healthcare professionals;
  • Conducted multiple internal investigations for pharmaceutical and medical device companies focusing on off label promotion, anti-kickback, and FDCA allegations;
  • Secured denial of class certification and dismissal of case against medical products manufacturer in securities fraud class action; 
  • Persuaded US Attorney’s Office and Securities and Exchange Commission to decline criminal and civil charges against hedge fund Founder and Lead Portfolio manager in insider-trading investigation;
  • Represented hedge fund Founder and Lead Portfolio manager in parallel federal criminal and SEC insider trading investigation; 
  • Secured denial of class certification and dismissal of case against financial software company in SEC fraud class action;
  • Conducted internal investigation for Board of Directors of financial institution focusing on internal audit and economic modeling functions;
  • Persuaded SEC and administrative oversight body to decline action against Special Committee of communications technology company in SEC fraud investigation and administrative delisting proceedings;
  • Persuaded Department of Justice and Securities Exchange Commission to decline charges against S&P 500 technology company in multi-year parallel federal civil and criminal fraud investigation;
  • Persuaded SEC to decline charges against former Chief Financial Officer and Chief Operating Officer of semi-conductor manufacturing company in SEC fraud investigation;
  • Represented CFO and Chief Compliance Officer of investment management company in SEC investigation and collateral administration proceedings concerning alleged market manipulation, securities fraud and disclosure violations;
  • Persuaded US Attorney’s Office to dismiss criminal charges against defendant in pro bono gang prosecution;
  • Persuaded US Attorney’s Office to dismiss civil forfeiture action.  

Professional Activities

Ms. Schulman is co-chair of the Boston Bar Association's Health Law Section, and serves on the Board of Directors of the Massachusetts Association of Criminal Defense Lawyers. She has been a Visiting Lecturer at Harvard Law School since 2010.  In 2013, she was a Visiting Professor at Srednerusskiy University in Russia, teaching US criminal law and criminal procedure. She has also been a Visiting Assistant Professor at Villanova University School of Law, teaching courses on criminal law, criminal procedure and white-collar crime. Ms. Schulman has conducted trainings nationally and internationally on criminal investigatory and enforcement matters and developments in healthcare and securities law. She is also a member of the First Circuit Criminal Justice Act Screening Committee and a member of the US District Court Criminal Justice Act Panel.


Skip Navigation Links.


JD, magna cum laude, Harvard Law School, 1993, President, Harvard Law Review

BA, Social Studies, magna cum laude, Harvard University, 1985

Bar Admissions


District of Columbia


The Hon. Abner J. Mikva, US Court of Appeals for the District of Columbia Circuit, 1993 - 1994

Government Experience

Skip Navigation Links.